BACKGROUND: Mucosal expression of interferon (IFN)-γ plays a pivotal role in the pathogenesis of inflammatory bowel disease (IBD) and IBD risk regions flank IFNG. The conserved IFNG rs1861494 T/C introduces a new CpG methylation site, is associated with disease severity and lack of therapeutic response in other infectious and immune-mediated disorders, and is in linkage disequilibrium with a ulcerative colitis (UC) disease severity region. It seems likely that CpG-altering single nucleotide polymorphisms modify methylation and gene expression. This study evaluated the association between rs1861494 and clinical, serologic, and methylation patterns in patients with IBD. METHODS: Peripheral T cells of UC and Crohn's disease (CD) patients were genotyped for rs1861494 and analyzed for allele-specific and IFNG promoter methylation. Serum antineutrophil cytoplasmic autoantibodies and IFN-γ secretion were measured by enzyme-linked immunosorbent assay and nucleoprotein complex formation by electrophoretic mobility shift assay. RESULTS: IFNG rs1861494 T allele carriage in patients with IBD was associated with enhanced secretion of IFN-γ. T allele carriage was associated in UC with high levels of antineutrophil cytoplasmic autoantibodies and faster progression to colectomy. In CD, it was associated with complicated disease involving a stricturing/penetrating phenotype. Likewise, IFNG rs1861494 displayed genotype-specific modulation of DNA methylation and transcription factor complex formation. CONCLUSIONS: This study reports the first association of IFNG rs1861494 T allele with enhanced IFN-γ secretion and known IBD clinical parameters indicative of more aggressive disease and serological markers associated with treatment resistance to anti-tumor necrosis factor therapy in patients with IBD. These data may be useful prognostically as predictors of early response to anti-tumor necrosis factor therapy to identify patients with IBD for improved personalized therapeutics.
BACKGROUND: Mucosal expression of interferon (IFN)-γ plays a pivotal role in the pathogenesis of inflammatory bowel disease (IBD) and IBD risk regions flank IFNG. The conserved IFNGrs1861494 T/C introduces a new CpG methylation site, is associated with disease severity and lack of therapeutic response in other infectious and immune-mediated disorders, and is in linkage disequilibrium with a ulcerative colitis (UC) disease severity region. It seems likely that CpG-altering single nucleotide polymorphisms modify methylation and gene expression. This study evaluated the association between rs1861494 and clinical, serologic, and methylation patterns in patients with IBD. METHODS: Peripheral T cells of UC and Crohn's disease (CD) patients were genotyped for rs1861494 and analyzed for allele-specific and IFNG promoter methylation. Serum antineutrophil cytoplasmic autoantibodies and IFN-γ secretion were measured by enzyme-linked immunosorbent assay and nucleoprotein complex formation by electrophoretic mobility shift assay. RESULTS:IFNGrs1861494 T allele carriage in patients with IBD was associated with enhanced secretion of IFN-γ. T allele carriage was associated in UC with high levels of antineutrophil cytoplasmic autoantibodies and faster progression to colectomy. In CD, it was associated with complicated disease involving a stricturing/penetrating phenotype. Likewise, IFNGrs1861494 displayed genotype-specific modulation of DNA methylation and transcription factor complex formation. CONCLUSIONS: This study reports the first association of IFNGrs1861494 T allele with enhanced IFN-γ secretion and known IBD clinical parameters indicative of more aggressive disease and serological markers associated with treatment resistance to anti-tumor necrosis factor therapy in patients with IBD. These data may be useful prognostically as predictors of early response to anti-tumor necrosis factor therapy to identify patients with IBD for improved personalized therapeutics.
Authors: Rivkah Gonsky; Richard L Deem; Carol J Landers; Carrie A Derkowski; Dror Berel; Dermot P B McGovern; Stephan R Targan Journal: Inflamm Bowel Dis Date: 2011-01 Impact factor: 5.325
Authors: Stephan R Targan; Carol J Landers; Huiying Yang; Michael J Lodes; Yingzi Cong; Konstantinos A Papadakis; Eric Vasiliauskas; Charles O Elson; Robert M Hershberg Journal: Gastroenterology Date: 2005-06 Impact factor: 22.682
Authors: Agustín Rolandelli; Joaquín M Pellegrini; Nicolás O Amiano; María C Santilli; María P Morelli; Florencia A Castello; Nancy L Tateosian; Alberto Levi; Nicolás Casco; Domingo J Palmero; Verónica E García Journal: Genes (Basel) Date: 2018-01-22 Impact factor: 4.096
Authors: Hazel Tye; Chien-Hsiung Yu; Lisa A Simms; Marcel R de Zoete; Man Lyang Kim; Martha Zakrzewski; Jocelyn S Penington; Cassandra R Harapas; Fernando Souza-Fonseca-Guimaraes; Leesa F Wockner; Adele Preaudet; Lisa A Mielke; Stephen A Wilcox; Yasunori Ogura; Sinead C Corr; Komal Kanojia; Konstantinos A Kouremenos; David P De Souza; Malcolm J McConville; Richard A Flavell; Motti Gerlic; Benjamin T Kile; Anthony T Papenfuss; Tracy L Putoczki; Graham L Radford-Smith; Seth L Masters Journal: Nat Commun Date: 2018-09-13 Impact factor: 14.919
Authors: Boyoung Shin; Robert L Kress; Philip A Kramer; Victor M Darley-Usmar; Susan L Bellis; Laurie E Harrington Journal: J Exp Med Date: 2018-06-18 Impact factor: 14.307
Authors: Ana Ogrinc Wagner; Verena Friedrich; Christian Barthels; Peggy Marconi; Andreas Blutke; Frank Brombacher; Thomas Brocker Journal: PLoS One Date: 2019-01-17 Impact factor: 3.240
Authors: Marianne R Spalinger; Marlene Schwarzfischer; Larissa Hering; Ali Shawki; Anica Sayoc; Alina Santos; Claudia Gottier; Silvia Lang; Katharina Bäbler; Annelies Geirnaert; Christophe Lacroix; Gabriel E Leventhal; Xuezhi Dai; David Rawlings; Andrew A Chan; Gerhard Rogler; Declan F McCole; Michael Scharl Journal: Mucosal Immunol Date: 2019-09-09 Impact factor: 7.313